BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting
03 oct. 2022 07h00 HE
|
BioCardia, Inc.
SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting
14 sept. 2022 07h00 HE
|
BioCardia, Inc.
Sunnyvale, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...